BiomX reports FDA clinical hold continues; DMC recommends adjusted dosing for Phase 2b CF study

BiomX Inc.

FDA continues evaluation of third-party nebulizer used in BX004 Phase 2b cystic fibrosis study; clinical hold remains.
Independent Data Monitoring Committee recommends adjusted dosing regimen; company updating trial protocol accordingly.
Topline results now expected in Q2 2026, pending availability of financial resources and other factors.
Company working with third-party manufacturer to address FDA follow-up requests; expects to lift hold.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.